Data from molecular analyses unveil diverse resistance mechanisms to endocrine therapy in breast cancer
Among the presented findings, a potential role for ESR1 gene fusions was observed
Frontline abemaciclib plus endocrine therapy showed superior efficacy compared to chemotherapy in aggressive HR+/HER2– breast cancer
The combination therapy with the CDK 4/6 inhibitor improved overall response rate compared to standard treatment
Promising antitumour activity presented for emerging targets in different solid tumours
Strategies to target MTAP deletion, KRAS G12D and ESR1 mutations, and CDK4 and CDK2 further expand the landscape of precision oncology
Physical activity is beneficial for patients with cancer, but also challenging
Evidence from tailored programmes in breast cancer show that a more holistic approach is needed to support patients to find the motivation to take up an active lifestyle
Pre-operative immunoradiation shows clinical benefit in patients with high-risk, early-stage breast cancer
Results from the Neo-CheckRay study report an acceptable toxicity profile with the addition of a PD-L1 inhibitor to neoadjuvant chemotherapy and stereotactic body radiation therapy
Early-stage immunotherapy significantly prolongs overall survival in triple-negative breast cancer
Final results from the KEYNOTE-522 study confirm that the integration of pembrolizumab into the treatment regimen has the potential to transform patient management, but careful patient selection and monitoring for toxicities will be crucial
Clinical activity reported for novel first-line combination strategies in advanced triple-negative breast cancer
Early-phase clinical trial results show promise to optimise the current standard of care by using dual-targeting agents and investigating the most effective chemotherapy backbone for PD-L1 blockade
Breastfeeding after breast cancer is feasible and safe
New data show that it does not increase the risk of breast cancer recurrence or development of secondary breast cancer in women, nor does it carry any health risks for the child
Taxane- and anthracycline-sparing regimens show promise in high-risk, early-stage breast cancer
High rates of pathological complete response were reported with neoadjuvant datopotamab deruxtecan plus durvalumab in patients with specific subtypes of breast cancer and at high risk of recurrence
Antibody–drug conjugates offer hope for patients with breast cancer including patients with brain metastases
New positive findings from research in advanced or metastatic breast cancer support the use of these agents in wider patient populations